Willems Rik, Exner Derek V
Cardiovascular Research Group, University of Calgary, Calgary, Canada.
J Interv Card Electrophysiol. 2004;10 Suppl 1:9-16. doi: 10.1023/B:JICE.0000011340.74632.ac.
Atrial fibrillation (AF) is associated with a significant morbidity and mortality, mainly due to an increased risk of thromboembolic stroke. Several large randomized trials have demonstrated the efficacy of oral anticoagulation to reduce this risk of ischemic events in patients with non-valvular AF. Despite the translation of these results into clear practice guidelines, oral anticoagulation remains underused. This reflects doubts about the real effectiveness of oral anticoagulation in daily practice. This paper gives an overview of the available evidence of the effectiveness of oral anticoagulation in population studies and tries to identify some remaining barriers in the prescription of oral anticoagulation in real life.
心房颤动（AF）与显著的发病率和死亡率相关，主要原因是血栓栓塞性中风风险增加。多项大型随机试验已证明口服抗凝药可降低非瓣膜性AF患者发生缺血性事件的风险。尽管这些结果已转化为明确的实践指南，但口服抗凝药的使用仍未得到充分利用。这反映出对口服抗凝药在日常实践中实际效果的怀疑。本文概述了人群研究中口服抗凝药有效性的现有证据，并试图找出在现实生活中口服抗凝药处方方面仍然存在的一些障碍。
